Study Information

What’s involved?

  • 4 days & nights inpatient stay
  • 1 quick follow-up appointment

This clinical trial has been approved by an independent ethics committee.

About the study

The medication is being developed as a potential new treatment for idiopathic pulmonary fibrosis (IPF), a disease that causes progressive, irreversible damage to the lungs. IPF typically affects adults over the age of 40. Currently there is a need for an effective treatment for those with IPF.

This medication works by preventing the spread of fibrosis (scarring) in IPF patients.

How do I find out more?

If you have already registered with us but would like more information about this study, please call 1800 243 733 or schedule a call back. You can also email us at quoting “Respiration Study”.

If you are interested in participating and have not previously registered as a participant with us, fill in your details in the form below and we’ll be in touch soon!

  • 4
    Nights Inpatient Stay
  • 1
    Outpatient Visit

Minimum Eligibility Requirements:

  • Healthy Males and Females
  • Aged 18 – 65 years old
  • BMI 18 – 32 kg/m²
  • Not taking any prescription medication or over the counter medication